Alnylam Pharmaceuticals, Inc.
ALNY
$438.93
$3.830.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 30.21% | 0.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 30.21% | 0.17% | |||
| Cost of Revenue | 101.23% | -30.91% | |||
| Gross Profit | 20.57% | 6.69% | |||
| SG&A Expenses | 34.74% | -18.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.11% | -17.50% | |||
| Operating Income | -189.61% | 117.19% | |||
| Income Before Tax | 15.00% | 78.55% | |||
| Income Tax Expenses | 94.67% | 114.41% | |||
| Earnings from Continuing Operations | -15.31% | 31.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.31% | 31.38% | |||
| EBIT | -189.61% | 117.19% | |||
| EBITDA | -106.94% | 135.70% | |||
| EPS Basic | -14.46% | 31.66% | |||
| Normalized Basic EPS | 16.95% | 79.12% | |||
| EPS Diluted | -14.46% | 31.66% | |||
| Normalized Diluted EPS | 16.95% | 79.12% | |||
| Average Basic Shares Outstanding | 0.73% | 0.43% | |||
| Average Diluted Shares Outstanding | 0.73% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||